迪哲（江苏）医药股份有限公司 信息披露暂缓与豁免业务管理制度 （三）董事、高级管理人员知悉或者应当知悉该重大事件发生时。 1 第一章 总则 第一条 为规范迪哲（江苏）医药股份有限公司（以下简称"公司"）的信 息披露暂缓与豁免行为，促进公司依法规范运作，维护公司股东、债权人及其利 益相关人的合法权益，依据《中华人民共和国证券法》《上市公司信息披露暂缓 与豁免管理规定》《上海证券交易所科创板股票上市规则》（以下简称"《上市 规则》"）和《迪哲（江苏）医药股份有限公司章程》（以下简称"《公司章 程》"）、《迪哲（江苏）医药股份有限公司信息披露管理办法》及其他有关规 定，结合公司实际情况，制定本制度。 第二条 公司按照《上市规则》及上海证券交易所（以下简称"上交所"）其他相 关业务规则的规定，实施信息披露暂缓、豁免业务的，适用本制度。 第三条 公司应当披露的信息存在《上市规则》及上交所其他相关业务规 则中规定的暂缓、豁免情形的，可以无须向上交所申请，由公司自行审慎判 断，并接受上交所对有关信息披露暂缓、豁免事项的事后监管。 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披露信 息，不得滥用暂缓或者豁免披露 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-35 迪哲（江苏）医药股份有限公司 关于变更注册资本、修订《公司章程》并办理 工商变更登记的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迪哲（江苏）医药股份有限公司（以下简称"公司"） 于 2025 年 5 月 28 日召开第二届董事会第十四次会议，审议通过了《关于调整公司治理结构及废 止监事会议事规则的议案》《关于变更注册资本、修订公司章程及议事规则并 办理工商变更登记的议案》，具体公告如下： 一、公司注册资本的变更情况 公司于 2025 年 4 月 18 日完成向特定对象发行有限售条件流通股，新增股 份 4,176.4808 万股在中国证券登记结算有限责任公司上海分公司（以下简称 "中登公司"）的登记，公司注册资本由人民币 417,648,086 元增加至人民币 459,412,894 元。 二、取消监事会的情况 根据《中华人民共和国公司法》《上市公司章程指引（2025 年修订）》等 法律、法规、规范性文件的规定，公司不再设置监事会，由公司董事会审 ...

证券代码：688192 证券简称：迪哲医药 公告编号：2025-36 迪哲（江苏）医药股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 23 日 14 点 30 分 召开地点：无锡市新吴区新阳路 50 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 23 日 至2025 年 6 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年6月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:1 ...

1. 审议通过《关于调整公司治理结构及废止监事会议事规则的议案》 证券代码：688192 证券简称：迪哲医药 公告编号：2025-34 迪哲（江苏）医药股份有限公司 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迪哲（江苏）医药股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日召开公司第二届监事会第十二次会议（以下简称"会议"）。本次会议通知 于 2025 年 5 月 16 日以邮件方式送达监事。会议应出席监事 3 人，实际出席监 事 3 人。会议的召集、召开程序以及召开方式符合相关法律法规以及《迪哲 （江苏）医药股份有限公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 全体监事对本次监事会会议议案进行了审议，经表决形成如下决议： 表决结果：同意 3 票，反对 0 票，弃权 0 票。 为贯彻落实新《公司法》及中国证监会的规定和要求，优化公司治理结 构，监事会同意取消公司监事会设置，同步废止现行《监事会议事规则》， 由公司董事会审计委员会 ...

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology industry, particularly focusing on innovative drugs and their potential in the market [1]. Core Insights - The report highlights the significant achievements of domestic innovative drugs showcased at the upcoming ASCO 2025 conference, emphasizing the growing innovation capabilities of Chinese pharmaceutical companies [6][7]. - A strategic collaboration between 3SBio and Pfizer regarding the PD-1/VEGF dual antibody has been established, which includes a global licensing agreement with potential payments up to $4.8 billion based on development milestones and sales performance [2][6]. - Three domestic Class 1 innovative drugs have been approved for market launch, targeting prevalent diseases such as influenza, cancer, and diabetes, marking a critical step in the innovation and internationalization of domestic original drugs [2][6]. Market Performance Review - During the period from May 17 to May 24, the Shanghai Composite Index closed at 3348.37, down 0.57%, while the pharmaceutical industry index rose by 1.78%, ranking first among 31 primary industry indices [1][12]. - The weekly performance of various sectors within the pharmaceutical industry showed positive growth, with notable increases in chemical preparations (3.49%), biological products (1.74%), and medical services (1.42%) [1][12]. Upcoming Events - The ASCO annual meeting, a major international conference in oncology, is scheduled to take place from May 30 to June 3, 2025, in Chicago, where numerous innovative research results from domestic companies are expected to be presented [6][7]. Key Companies to Watch - The report suggests focusing on companies with strong innovation capabilities, including Heng Rui Medicine, Innovent Biologics, BeiGene, and 3SBio, as they are expected to showcase significant advancements at ASCO 2025 [7][19]. - It also recommends monitoring companies involved in high-end medical devices and those benefiting from market concentration in chain pharmacies and comprehensive medical services [8][19].

Core Viewpoint - Dizh Medical (688192) announced that its two innovative products, DZD8586 and DZD6008, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, highlighting the company's competitive advantages in the fields of hematological malignancies and lung cancer [1] Group 1: DZD8586 in B-NHL and CLL/SLL - DZD8586 is expected to provide a new treatment option for patients with B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - A summary analysis of a Phase I/II clinical study involving 51 patients with relapsed/refractory CLL/SLL showed an objective response rate (ORR) of 84.2% at a recommended dose of 50mg, indicating good anti-tumor efficacy and manageable safety [2] - DZD8586 also demonstrated anti-tumor activity in a Phase II study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with promising results to be presented at the 2025 European Hematology Association (EHA) annual meeting [2][3] Group 2: DZD6008 in NSCLC - DZD6008 is anticipated to address unmet clinical needs in non-small cell lung cancer (NSCLC), particularly for patients with EGFR mutations who have undergone multiple lines of treatment [4] - Early clinical data from the TIAN-SHAN2 study showed that 83.3% of 12 patients with advanced NSCLC experienced tumor shrinkage after treatment with DZD6008, demonstrating durable anti-tumor activity and good tolerability [4][5] - DZD6008 exhibits excellent blood-brain barrier penetration, with a concentration ratio in cerebrospinal fluid exceeding 1, indicating its potential effectiveness in patients with brain metastases [4][5] Group 3: Company Strategy and Future Outlook - The founder and CEO of Dizh Medical emphasized the company's commitment to accelerating the global development of DZD8586 and DZD6008, aiming to provide more treatment options for patients with B-NHL and NSCLC [6] - The promising clinical data presented at ASCO reinforces the company's confidence in advancing DZD8586 into Phase III clinical trials [6]

2025.05. 24 本文字数：2099，阅读时长大约3分钟 Wind数据显示，在已经披露2024年年报的药企中，高管年薪在千万以上绝非个例。在俞德超之前， 还有多家药企的高管薪酬过亿。 作者 | 第一财经 陈敏之 近日，理想汽车（02015.HK/LI.US）创始人、董事长兼CEO李想2024年领取6.39亿元"天价年薪"冲 上热搜引发热议。 事实上，创新药企业里，也不乏上亿年薪的创始人和CEO，但有所不同的是，这些创新药公司多数 还没有走完商业化历程，公司处于连年亏损状态。比如刚刚敲钟上市的映恩生物（9606.HK），创 始人朱忠远去年薪酬8556万元，公司同期亏损超过10亿元。近期三次递表港交所的英矽智能，执行 董事任峰2024年薪酬总计307.3万美元，公司当年净亏损1709.6万美元。 这样例子在创新药企业里比比皆是。Wind数据显示，思路迪医药股份（1244.HK）董事长龚兆龙 2024年的薪酬为2067万元，六年的薪酬总额则超过5亿元，而公司六年亏损超40亿元。 高薪背后，是创新药行业整体尚未步出资本寒冬。高管的收入与公司业绩形成的强烈反差，引发市场 对行业价值导向的深度思考。 年薪千万比比皆 ...

Group 1 - The article highlights the stark contrast between high executive salaries and the financial performance of companies in the innovative drug sector, where many firms are still unprofitable [2][10][11] - Li Xiang, the founder and CEO of Li Auto, received a salary of 639 million RMB in 2024, sparking discussions about excessive executive compensation in the context of ongoing company losses [2][3] - Companies like InnoCare Pharma and Sihuan Pharmaceutical have reported significant executive salaries while simultaneously posting substantial losses, raising questions about the sustainability of such compensation structures [5][10] Group 2 - The article provides examples of high executive salaries in the innovative drug industry, including Zhu Zhongyuan of InnoCare Pharma with a salary of 85.56 million RMB in 2024, despite the company losing over 1 billion RMB [3][10] - Other notable salaries include Yu Dechao of Innovent Biologics, who earned approximately 136 million RMB, and Gong Zhaolong of Sihuan Pharmaceutical, whose total compensation exceeded 500 million RMB over six years [5][10] - The trend of high salaries persists even among companies that have not yet commercialized their products, such as Yingxi Intelligent and Weili Zhibo, which have reported significant losses [11]

Core Insights - DIZHE Pharmaceutical announced the presentation of two innovative drugs, DZD8586 and DZD6008, at the 2025 ASCO annual meeting, focusing on their advancements in treating B-cell non-Hodgkin lymphoma (B-NHL) and non-small cell lung cancer (NSCLC) [1][2] Group 1: DZD8586 - DZD8586 is a first-in-class, non-covalent dual-target inhibitor of LYN/BTK that can fully penetrate the blood-brain barrier [1] - In a study involving 51 patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DZD8586 demonstrated an objective response rate (ORR) of 84.2% at a 50mg dosage, with 78.9% of patients continuing treatment [1] - Another study on DZD8586 for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) showed good anti-tumor activity and safety at both 50mg and 75mg dosages [2] Group 2: DZD6008 - DZD6008 is a novel, highly selective EGFR tyrosine kinase inhibitor (TKI) that also fully penetrates the blood-brain barrier [2] - In a study of 12 advanced NSCLC patients with various EGFR mutation types, DZD6008 exhibited encouraging and durable anti-tumor activity with good tolerability [2] - The ongoing research aims to further validate the efficacy and safety of DZD6008 in a broader population, potentially enhancing treatment options for advanced lung cancer patients [2] Group 3: Company Strategy and Future Plans - The CEO of DIZHE Pharmaceutical expressed confidence in advancing DZD8586 to Phase III clinical trials, highlighting its significant efficacy in treating CLL/SLL [2] - The company aims to accelerate the global development of both DZD8586 and DZD6008, seeking to provide more treatment options for patients with B-NHL and NSCLC [2]

Group 1 - Public funds have actively participated in the A-share private placement market, with a total allocation amount of 9.785 billion yuan and a floating profit of 1.694 billion yuan, resulting in an overall floating profit ratio of 17.32% as of May 20, 2025 [1][3] - The top-performing public fund is Yimi Fund, achieving a floating profit ratio of 49.49% with a floating profit of 39.588 million yuan from an allocation of 80 million yuan [1][3] - Companies like Leshan Power and Sheng Tai Co. have shown significant floating profits, with Leshan Power leading at a floating profit ratio of 178% [3][4] Group 2 - Private funds have also shown strong performance, with 27 private institutions participating in 23 A-share companies, achieving a total allocation of 1.943 billion yuan and a floating profit of 528 million yuan, resulting in a floating profit ratio of 27.19% as of May 21, 2025 [2][6] - Small-scale private funds have excelled, with Lihua Investment achieving a floating profit ratio of 178.04% from a single allocation of 810,000 yuan [7][8] - The overall performance of the private placement market indicates a trend towards higher returns in sectors such as new energy, semiconductors, and high-end manufacturing, which account for over 70% of the high floating profit ratios [9]